Abstract
Background: Chemerin is a newly discovered adipokine, whose circulating concentration is increased in obesity. Aim: To elucidate whether the increased circulating chemerin concentrations in obese subjects are associated with the increase of fat mass, the increase in chemerin gene expression in adipose tissue or both. Material/Subjects and Methods: Serum chemerin concentrations in 20 non-obese healthy volunteers and 21 non-diabetic obese subjects were measured using ELISA. Chemerin mRNA and chemerin protein levels in visceral and subcutaneous adipose tissues of obese subjects were analyzed by Real-Time PCR and Western blot respectively. Results: We found that the serum chemerin concentrations were significantly higher in obese subjects than in controls and positively correlated with BMI, fat mass and body mass. Moreover serum chemerin concentrations were correlated positively with serum CRP concentrations independently of BMI. No correlation was found between the chemerin mRNA and chemerin protein levels in visceral and subcutaneous adipose tissues and BMI, fat mass, or body weight. Likewise, there was no correlation between the serum chemerin concentrations and the levels of chemerin mRNA and protein in adipose tissue of obese patients. Multiple regression analysis suggests that BMI was the main predictor of serum chemerin concentration. In contrast to chemerin, both serum leptin concentrations and adipose tissue leptin mRNA levels positively correlated with BMI. Conclusions: The results presented here indicate that serum chemerin concentrations correlated with BMI, whereas chemerin mRNA levels in adipose tissue did not. Thus the elevated circulating chemerin concentration in obese, non-diabetic patients was mainly associated with the increased BMI.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Terra X, Auguet T, Porras JA, et al. Anti-inflammatory profile of FTO gene expression in adipose tissues from morbidly obese women. Cell Physiol Biochem 2010, 26: 1041–50.
Knerr I, Herzog D, Rauh M, Rascher W, Horbach T. Leptin and ghrelin expression in adipose tissues and serum levels in gastric banding patients. Eur J Clin Invest 2006, 36: 389–94.
Hindle AK, Edwards C, McCaffrey T, Fu SW, Brody F. Reactivation of adiponectin expression in obese patients after bariatric surgery. Surg Endosc 2010, 24: 1367–73.
Bozaoglu K, Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007, 148: 4687–94.
Goralski KB, McCarthy TC, Hanniman EA, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007, 282: 28175–88.
Zabel BA, Ohyama T, Zuniga L, et al. Chemokine-like receptor 1 expression by macrophages in vivo: regulation by TGF-beta and TLR ligands. Exp Hematol 2006, 34: 1106–14.
Kaur J, Adya R, Tan BK, Chen J, Randeva HS. Identification of chemerin receptor (ChemR23) in human endothelial cells: chemerin-induced endothelial angiogenesis. Biochem Biophys Res Commun 2010, 391: 1762–8.
Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population — a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008, 152: 217–21.
Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab 2010, 21: 660–7.
Bozaoglu K, Segal D, Shields KA, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 2009, 94: 3085–8.
Weigert J, Neumeier M, Wanninger J, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 2010, 72: 342–8.
Lehrke M, Becker A, Greif M, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009, 161: 339–44.
Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56: 1010–3.
Parlee SD, Ernst MC, Muruganandan S, Sinal CJ, Goralski KB. Serum chemerin levels vary with time of day and are modified by obesity and tumor necrosis factor-{alpha}. Endocrinology 2010, 151: 2590–602.
Sell H, Laurencikiene J, Taube A, et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009, 58: 2731–40.
Kralisch S, Weise S, Sommer G, et al. Interleukin-1 beta induces the novel adipokine chemerin in adipocytes in vitro. Regul Pept 2009, 154: 102–6.
Sell H, Divoux A, Poitou C, et al. Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery. J Clin Endocrinol Metab 2010, 95: 2892–6.
Ress C, Tschoner A, Engl J, et al. Effect of bariatric surgery on circulating chemerin levels. Eur J Clin Invest 2010, 40: 277–80.
Takahashi M, Takahashi Y, Takahashi K, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008, 582: 573–8.
Catalan V, Gomez-Ambrosi J, Rodriguez A, et al. Increased levels of chemerin and its receptor, chemokine-like receptor-1, in obesity are related to inflammation: tumor necrosis factor-alpha stimulates mRNA levels of chemerin in visceral adipocytes from obese patients. Surg Obes Relat Dis 2013, 9: 306–14.
Chakaroun R, Raschpichler M, Kloting N, et al. Effects of weight loss and exercise on chemerin serum concentrations and adipose tissue expression in human obesity. Metabolism 2012, 61: 706–14.
Alfadda AA, Sallam RM, Chishti MA, et al. Differential patterns of serum concentration and adipose tissue expression of chemerin in obesity: Adipose depot specificity and gender dimorphism. Mol Cells 2012, 33: 591–6
Fain JN, Tagele BM, Cheema P, Madan AK, Tichansky DS. Release of 12 adipokines by adipose tissue, nonfat cells, and fat cells from obese women. Obesity (Silver Spring) 2010, 18: 890–6.
Piehler AP, Grimholt RM, Ovstebo R, Berg JP. Gene expression results in lipopolysaccharide-stimulated monocytes depend significantly on the choice of reference genes. BMC Immunol 2010, 11: 21.
Tan BK, Chen J, Farhatullah S, et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009, 58: 1971–7.
Moreno-Aliaga MJ, Lorente-Cebrian S, Martinez JA. Regulation of adipokine secretion by n-3 fatty acids. Proc Nutr Soc 2010, 69: 324–32.
Swierczynski J. Leptin and age-related down-regulation of lipogenic enzymes genes expression in rat white adipose tissue. J Physiol Pharmacol 2006, 57(Suppl 6): 85–102.
Fain JN, Sacks HS, Buehrer B, et al. Identification of omentin mRNA in human epicardial adipose tissue: comparison to omentin in subcutaneous, internal mammary artery periadventitial and visceral abdominal depots. Int J Obes (Lond) 2008, 32: 810–5.
Hurtado del Pozo C, Calvo RM, Vesperinas-Garcia G, et al. IPO8 and FBXL10: new reference genes for gene expression studies in human adipose tissue. Obesity (Silver Spring) 2010, 18: 897–903.
Shin HY, Lee DC, Chu SH, et al. Chemerin levels are positively correlated with abdominal visceral fat accumulation. Clin Endocrinol (Oxf) 2011, 77: 47–50.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sledzinski, T., Korczynska, J., Hallmann, A. et al. The increase of serum chemerin concentration is mainly associated with the increase of body mass index in obese, non-diabetic subjects. J Endocrinol Invest 36, 428–434 (2013). https://doi.org/10.3275/8770
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3275/8770